# Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

> **NCT00236041** · PHASE2 · COMPLETED · sponsor: **Cephalon** · enrollment: 38 (—)

## Conditions studied

- Cancer
- Breakthrough Pain

## Interventions

- **DRUG:** ACTIQ®

## Key facts

- **NCT ID:** NCT00236041
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 38 (—)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236041, "Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00236041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*